Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cognitive Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$58,442,363

24,002 payments

Through program year 2025, Cognitive Clinical Trials LLC is reported as receiving $58,442,363 in research payments, across 24,002 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,009,776 383
2024 Research $7,264,254 665
2023 Research $14,781,906 13,904
2022 Research $29,708,162 8,714
2021 Research $2,965,285 230
2020 Research $430,780 71
2019 Research $282,201 35

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $36,522,000 21,922 payments
  2. Pfizer Inc. $11,866,423 925 payments
  3. Abbott Laboratories $2,764,083 146 payments
  4. GlaxoSmithKline, LLC. $1,585,723 142 payments
  5. Eli Lilly and Company $1,158,041 27 payments
  6. AbbVie, Inc. $1,144,278 313 payments
  7. Novavax Inc $716,165 88 payments
  8. Novartis Pharmaceuticals Corporation $646,064 36 payments
  9. Janssen Research & Development, LLC $370,347 50 payments
  10. Regeneron Pharmaceuticals, Inc. $243,510 80 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $16,486,003 191 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $5,423,183 475 payments
  3. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $5,034,431 2,602 payments
  4. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $3,853,671 6,456 payments
  5. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $3,247,497 167 payments
  6. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $2,750,840 5,702 payments
  7. A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age $2,648,652 2,815 payments
  8. Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults $1,762,001 2,293 payments
  9. A Phase III, Randomized, Open-Label, Controlled, Multi-Center Study to $1,053,919 51 payments
  10. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $1,047,887 46 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record